Selank...for stress reduction

[John Juan]

Selank-induced normalizing effects on the integrative brain activity and biogenic amine level disorders due to antenatal hypoxia
(PMID:17385425)

Abstract

The effects of Selank synthetic analog of Tuftsin, representing the heptapeptide forming Thr-Lys-Pro-Arg-Pro-Gly-Pro, on behavior and serotonin/noradrenalin concentrations in brain were investigated in adult rats exposed to hypoxia during 14-16 days of gestation. It was revealed that injection of Selank (300 mkg/kg, i/p) increased 2--3-fold (p < 0.01) the sensory attention, facilitated 1.5-fold the learning capacity (p < 0.01), normalized exploratory activity in the open field and hole board, and recovered the balance of serotonergic and noradrenergic brain system activity. The data obtained demonstrate the possibility of Selank to compensate for long-lasting negative effects of antenatal hypoxia on integrative brain activity and brain monoamine level.

 

[John Juan]

P-1114 - Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic selank

Introduction
Heptapeptide Selank approved for the treatment of Generalized Anxiety Disorder (GAD). Studies revealed that Selank acts as an anxiolytic with stimulatory and cognitive enhancing properties. Though time to treatment response significantly varied in patients and this issue has not been studied.

Objectives
Individual treatment response analysis in Selank-treated patients with GAD.

Aims
To compare clinical state and EEG changes in patients with different time to treatment response to Selank.

Methods
20 patients aged 24–52 y.o. with GAD according to DSM-IV were included. Selank was administered at the dose 2700 μg/day intranasally. Study utilized valid clinical scales and pharmaco-EEG.

Results
40% of patients were rapid responders (RR) and characterized by abrupt reduction of whole set of symptoms in first 1–3 Days. At the Day 3 Hamilton Anxiety Rating Scale (HARS) mean total score [SD] reduced from 20.3[11.9] to 7.0[2.9] (p < 0.01). 60% of patients responded gradually (conventional responders - CR). Clinically significant changes of mean HARS total score from 16.1[7.2] to 6.2[4.7] were achieved at Day 14, p < 0.01. In contrast to CR, RR demonstrated obvious EEG-reaction after single dose (900 μg) with increase of beta-rhythm, decrease of theta- and low frequencies of alpha-rhythm (all p < 0.05). Initially RR and CR significantly differed by the score of asthenic and cognitive symptoms (p < 0.05).

Conclusions
Data that peptide anxiolytic drug Selank in patients with GAD exert significant individual variability of therapeutic effect, including rapid effectiveness, confirmed. RR had more asthenic and cognitive symptoms and characterized by a higher EEG-reactivity than CR.

 

[John Juan]

Selank and its derivatives had a significant antiulcer effect by increasing the resistance of the gastric mucosa to the factors that contributed to the formation of ulcers.

 

[John Juan]

The neurobiochemical spectrum of selank action combines mechanisms which are characteristics of antidepressants and psychostimulants: activation of the brain monoaminergic systems, dopamine synthesis and turnover, and modulation of the tyrosine hydroxylase activity.

 

[John Juan]

I recommended Selank to a veteran with PTSD. It seems the perfect choice to me.

 

[John Juan]

[Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA].

[Article in Russian]
Semenova TP, kozlovskiĭ II, Zakharova NM, Kozlovskaia MM.

Abstract

Effects of the peptide drugs selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and tuftsin (Thr-Lys-Pro-Arg) on the metabolism of serotonin (5-hydroxytryptamine, 5-HT) in the brain of Wistar rats preliminarily treated with the 5-HT-synthesis inhibitor p-chlorophenylalanine (PCPA, 320 mg/kg, i.p., 4 days before experiment) have been studied on a group of 87 matured rats. It is established that selank enhances the 5-HT metabolism in the brain stem 30 min after injection to animals pretreated with PCPA. In contrast to selank, tuftsin induced no changes in the 5-HT metabolism in the brain stem and decreased it in the neocortex on the same time scale. The data obtained suggest that the peptide drug selank can be used for the correction of disturbances induced by a decrease in 5-HT metabolism.

 

[SoCalMK6GTI]

It's late and this is a lot to take in but...

I have mild PTSD from OEF and I'm very OCD, I wonder how well this would help me. Major anxiety when locking doors and trying to leave the house and also when driving anything similar to Afghanistan.

 

[John Juan]

It's late and this is a lot to take in but...

I have mild PTSD from OEF and I'm very OCD, I wonder how well this would help me. Major anxiety when locking doors and trying to leave the house and also when driving anything similar to Afghanistan.

Of all the peptides out today this looks like the best one to help you IMO.
From users I've talked to they said it shut off the background noise that causes distress, you are aware of what would bother you but you don't seem to be concerned with it.

 

[John Juan]

[Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice].

AuthorsSarkisova KIu, et al. Show all Journal
Zh Vyssh Nerv Deiat Im I P Pavlova. 2008 Mar-Apr;58(2):226-37. Article in Russian.

Affiliation
Abstract
A synthetic derivative of the endogenous peptide tuftsin heptapeptide selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) possesses an anxiolytic and psychostimulant effect, and represents a working element of a new peptide drug having completed the third phase of the clinical testing as a selective anxiolytic. The neurobiochemical spectrum of selank action combines mechanisms which are characteristics of antidepressants and psychostimulants: activation of the brain monoaminergic systems, dopamine synthesis and turnover, and modulation of the tyrosine hydroxylase activity. The aim of this study was to investigate the effect of selank in a new model of inherited (genetically-based) symptoms of depression in behavior of inbred WAG/Rij rats in comparison with its effect on situation-provoked symptoms of depression in behavior of BALB/c mice. Outbred Wistar rats constituted control group. Selank in high doses (1000-2000 microg/kg), after repeated injection counteracted symptoms of depression in behavior of WAG/Rij rats (increased immobilization in the forced swimming test and decreased sucrose intake or preference (anhedonia)). Selank in low doses (100 and 300 microg/kg) after single injection reduced the duration of immobility of BALB/c mice in the forced swimming test, but did not exert significant effect after repeated injection or after injection in high doses (600 and 900 microg/kg). Selank did not affect the level of general locomotor activity and anxiety in WAG/Rij rats, and did not exert substantial effect on the behavior of control Wistar rats. The results demonstrate the presence of antidepressant component in the spectrum of neuropsychotrophyc activity of selank and indicate the higher reliability of a new experimental model of depression (the WAG/Rij rats) as compared to the standard forced swimming test for the determination of antidepressant activity of a pharmacological drug.

 

[John Juan]

Selank has no sedating or cognitive side effects and no associated addiction or withdrawal syndrome.